Literature DB >> 22489724

Chelating agents for neurodegenerative diseases.

R J Ward1, D T Dexter, R R Crichton.   

Abstract

It has become apparent in the last years that metal ion homeostasis and its dysfunction which results in increased accumulation in brain, notably of copper, iron and zinc, may be associated with a number of neurodegenerative diseases, such that chelation therapy may be one therapeutic option. We briefly outline chelators currently available together with strategies to develop new chelators capable of crossing the blood-brain-barrier. The homeostasis of iron in brain together with changes in brain iron with ageing are reviewed as well as the role of iron in Parkinson's disease, and the potential of chelation therapy in PD. Copper and zinc homeostasis in brain and age associated changes are then outlined, along with a discussion of the possible involvement of Zn, Cu and Fe in Alzheimer's disease. We conclude with a brief summary of chelation therapy in AD.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22489724     DOI: 10.2174/092986712800609689

Source DB:  PubMed          Journal:  Curr Med Chem        ISSN: 0929-8673            Impact factor:   4.530


  15 in total

Review 1.  Coherent and Contradictory Facts, Feats and Fictions Associated with Metal Accumulation in Parkinson's Disease: Epicenter or Outcome, Yet a Demigod Question.

Authors:  Mohd Sami Ur Rasheed; Sonam Tripathi; Saumya Mishra; Mahendra Pratap Singh
Journal:  Mol Neurobiol       Date:  2016-08-01       Impact factor: 5.590

2.  Characterization of the neuroprotective potential of derivatives of the iron chelating drug deferiprone.

Authors:  Pamela Maher; George J Kontoghiorghes
Journal:  Neurochem Res       Date:  2015-01-06       Impact factor: 3.996

3.  Investigation of the encapsulation of metal cations (Cu2+, Zn2+, Ca2+ and Ba2+) by the dipeptide Phe-Phe using natural bond orbital theory and molecular dynamics simulation.

Authors:  Snehasis Bhunia; Ajeet Singh; Animesh K Ojha
Journal:  J Mol Model       Date:  2017-02-22       Impact factor: 1.810

4.  Effects of Aluminium on Rat Brain Mitochondria Bioenergetics: an In vitro and In vivo Study.

Authors:  Javier Iglesias-González; Sofía Sánchez-Iglesias; Andrés Beiras-Iglesias; Estefanía Méndez-Álvarez; Ramón Soto-Otero
Journal:  Mol Neurobiol       Date:  2016-01-07       Impact factor: 5.590

5.  Synthesis and biological evaluation of (acyl)hydrazones and thiosemicarbazones obtained via in situ condensation of iminium salts with nitrogen-containing nucleophiles.

Authors:  Chiara Caneva; Silvana Alfei; Monica De Maria; Cristina Ibba; Ilenia Delogu; Andrea Spallarossa; Roberta Loddo
Journal:  Mol Divers       Date:  2015-06-16       Impact factor: 3.364

Review 6.  The iron regulatory capability of the major protein participants in prevalent neurodegenerative disorders.

Authors:  Bruce X Wong; James A Duce
Journal:  Front Pharmacol       Date:  2014-04-21       Impact factor: 5.810

Review 7.  Importance and management of micronutrient deficiencies in patients with Alzheimer's disease.

Authors:  Bárbara Rita Cardoso; Cristiane Cominetti; Silvia Maria Franciscato Cozzolino
Journal:  Clin Interv Aging       Date:  2013-05-10       Impact factor: 4.458

8.  Transition metals activate TFEB in overexpressing cells.

Authors:  Karina A Peña; Kirill Kiselyov
Journal:  Biochem J       Date:  2015-06-11       Impact factor: 3.857

Review 9.  Iron deposits in the chronically inflamed central nervous system and contributes to neurodegeneration.

Authors:  Hjalte Holm Andersen; Kasper Bendix Johnsen; Torben Moos
Journal:  Cell Mol Life Sci       Date:  2013-11-12       Impact factor: 9.261

10.  Assessing plasma levels of selenium, copper, iron and zinc in patients of Parkinson's disease.

Authors:  Hai-Wen Zhao; Jie Lin; Xue-Bao Wang; Xing Cheng; Jian-Yong Wang; Bei-Lei Hu; Yan Zhang; Xiong Zhang; Jian-Hong Zhu
Journal:  PLoS One       Date:  2013-12-10       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.